vs
Side-by-side financial comparison of Spero Therapeutics, Inc. (SPRO) and Winchester Bancorp, Inc. (WSBK). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $6.4M, roughly 2.0× Winchester Bancorp, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 16.7%, a 234.0% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 45.8%).
Winchester Bancorp, Inc. (Maryland) is a regional bank holding company operating community banking outlets across Maryland. It provides a full range of retail and commercial financial services, including deposit accounts, mortgage loans, small business loans, and wealth management solutions, serving individual consumers and local small to medium-sized enterprise clients.
SPRO vs WSBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $12.6M | $6.4M |
| Net Profit | $31.5M | $1.1M |
| Gross Margin | — | — |
| Operating Margin | — | 20.9% |
| Net Margin | 250.7% | 16.7% |
| Revenue YoY | 24080.8% | 45.8% |
| Net Profit YoY | 250.9% | 187.9% |
| EPS (diluted) | $0.56 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.6M | $6.4M | ||
| Q3 25 | $0 | $5.8M | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $12.0K | $4.4M | ||
| Q4 24 | $52.0K | $4.4M | ||
| Q3 24 | $65.0K | — | ||
| Q2 24 | $114.0K | — | ||
| Q1 24 | $140.0K | — |
| Q4 25 | $31.5M | $1.1M | ||
| Q3 25 | $-7.4M | $962.0K | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-13.9M | $305.0K | ||
| Q4 24 | — | $373.0K | ||
| Q3 24 | $-17.1M | — | ||
| Q2 24 | $-17.9M | — | ||
| Q1 24 | $-12.7M | — |
| Q4 25 | — | 20.9% | ||
| Q3 25 | — | 22.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | -122758.3% | 8.5% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | -28604.6% | — | ||
| Q2 24 | -16720.2% | — | ||
| Q1 24 | -9987.1% | — |
| Q4 25 | 250.7% | 16.7% | ||
| Q3 25 | — | 16.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | -115550.0% | 7.0% | ||
| Q4 24 | — | 8.4% | ||
| Q3 24 | -26380.0% | — | ||
| Q2 24 | -15668.4% | — | ||
| Q1 24 | -9049.3% | — |
| Q4 25 | $0.56 | $0.12 | ||
| Q3 25 | $-0.13 | $0.11 | ||
| Q2 25 | $-0.03 | — | ||
| Q1 25 | $-0.25 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.32 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $-0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.3M | $54.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $59.0M | $118.2M |
| Total Assets | $68.9M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.3M | $54.8M | ||
| Q3 25 | $48.6M | $57.7M | ||
| Q2 25 | $31.2M | — | ||
| Q1 25 | $48.9M | $66.6M | ||
| Q4 24 | $52.9M | $41.5M | ||
| Q3 24 | $76.3M | — | ||
| Q2 24 | $63.5M | — | ||
| Q1 24 | $82.3M | — |
| Q4 25 | $59.0M | $118.2M | ||
| Q3 25 | $26.5M | $117.0M | ||
| Q2 25 | $32.8M | — | ||
| Q1 25 | $33.8M | $80.9M | ||
| Q4 24 | $46.1M | $80.3M | ||
| Q3 24 | $65.5M | — | ||
| Q2 24 | $80.5M | — | ||
| Q1 24 | $96.2M | — |
| Q4 25 | $68.9M | $1.0B | ||
| Q3 25 | $54.2M | $1.0B | ||
| Q2 25 | $62.1M | — | ||
| Q1 25 | $77.7M | $923.1M | ||
| Q4 24 | $110.5M | $894.1M | ||
| Q3 24 | $135.2M | — | ||
| Q2 24 | $149.9M | — | ||
| Q1 24 | $167.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.4M | $1.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.26× | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.4M | $1.6M | ||
| Q3 25 | $17.4M | $1.4M | ||
| Q2 25 | $-17.7M | — | ||
| Q1 25 | $-4.0M | $848.0K | ||
| Q4 24 | $-23.4M | — | ||
| Q3 24 | $12.8M | — | ||
| Q2 24 | $-18.7M | — | ||
| Q1 24 | $5.9M | — |
| Q4 25 | -0.26× | 1.44× | ||
| Q3 25 | — | 1.41× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.78× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
